blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3625227

EP3625227 - BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  21.07.2023
Database last updated on 14.11.2024
FormerThe patent has been granted
Status updated on  12.08.2022
FormerGrant of patent is intended
Status updated on  13.04.2022
FormerRequest for examination was made
Status updated on  05.03.2022
FormerGrant of patent is intended
Status updated on  17.11.2021
FormerRequest for examination was made
Status updated on  21.02.2020
FormerThe international publication has been made
Status updated on  23.11.2018
Formerunknown
Status updated on  01.06.2018
Most recent event   Tooltip24.05.2024Lapse of the patent in a contracting state
New state(s): IT		published on 26.06.2024  [2024/26]
Applicant(s)For all designated states
Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil / CH
[2020/13]
Inventor(s)01 / BOSS, Christoph
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil / CH
02 / CORMINBOEUF, Olivier
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil / CH
03 / FRETZ, Heinz
Oertli 40c
3654 Gunten / CH
04 / LYOTHIER, Isabelle
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil / CH
05 / POZZI, Davide
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil / CH
06 / RICHARD-BILDSTEIN, Sylvia
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil / CH
07 / SIENDT, Herv
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil / CH
08 / SIFFERLEN, Thierry
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil / CH
 [2020/13]
Representative(s)Velker, Jörg
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil / CH
[2020/13]
Application number, filing date18725497.417.05.2018
[2020/13]
WO2018EP62843
Priority number, dateWO2017EP6198718.05.2017         Original published format: PCT/EP2017/061987
[2020/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018210987
Date:22.11.2018
Language:EN
[2018/47]
Type: A1 Application with search report 
No.:EP3625227
Date:25.03.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 22.11.2018 takes the place of the publication of the European patent application.
[2020/13]
Type: B1 Patent specification 
No.:EP3625227
Date:14.09.2022
Language:EN
[2022/37]
Search report(s)International search report - published on:EP22.11.2018
ClassificationIPC:C07D413/14, C07D405/12, C07D409/12, C07D409/14, C07D417/14, A61P35/00, A61K31/506
[2020/13]
CPC:
C07D409/14 (EP,KR,US); C07D413/14 (EP,KR,US); A61K31/506 (EP,KR);
A61K45/06 (EP,KR); A61P35/00 (EP,KR); C07D405/12 (EP,KR,US);
C07D409/12 (EP,KR); C07D417/14 (EP,KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/13]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:BENZOFURAN- UND BENZOTHIOPHENDERIVATE ALS PGE2-REZEPTOR-MODULATOREN[2020/13]
English:BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS[2020/13]
French:DÉRIVÉS DE BENZOFURANE ET DE BENZOTHIOPHÈNE UTILISÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR PGE2[2020/13]
Entry into regional phase18.12.2019National basic fee paid 
18.12.2019Designation fee(s) paid 
18.12.2019Examination fee paid 
Examination procedure18.12.2019Examination requested  [2020/13]
18.12.2019Date on which the examining division has become responsible
11.08.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
07.10.2020Amendment by applicant (claims and/or description)
18.11.2021Communication of intention to grant the patent
03.03.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
14.04.2022Communication of intention to grant the patent
05.08.2022Fee for grant paid
05.08.2022Fee for publishing/printing paid
05.08.2022Receipt of the translation of the claim(s)
Opposition(s)15.06.2023No opposition filed within time limit [2023/34]
Request for further processing for:07.10.2020Request for further processing filed
07.10.2020Full payment received (date of receipt of payment)
Request granted
21.10.2020Decision despatched
Fees paidRenewal fee
02.06.2020Renewal fee patent year 03
31.05.2021Renewal fee patent year 04
31.05.2022Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL14.09.2022
AT14.09.2022
CZ14.09.2022
DK14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
IT14.09.2022
LT14.09.2022
LV14.09.2022
MC14.09.2022
NL14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SI14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
IE17.05.2023
LU17.05.2023
BE31.05.2023
[2024/26]
Former [2024/24]AL14.09.2022
AT14.09.2022
CZ14.09.2022
DK14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
MC14.09.2022
NL14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SI14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
IE17.05.2023
LU17.05.2023
BE31.05.2023
Former [2024/21]AL14.09.2022
AT14.09.2022
CZ14.09.2022
DK14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
MC14.09.2022
NL14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SI14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
IE17.05.2023
LU17.05.2023
Former [2024/08]AL14.09.2022
AT14.09.2022
CZ14.09.2022
DK14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
MC14.09.2022
NL14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SI14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
LU17.05.2023
Former [2023/37]AL14.09.2022
AT14.09.2022
CZ14.09.2022
DK14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
NL14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SI14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
Former [2023/33]AL14.09.2022
AT14.09.2022
CZ14.09.2022
DK14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
NL14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
Former [2023/30]AL14.09.2022
AT14.09.2022
CZ14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
NL14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
Former [2023/29]AL14.09.2022
AT14.09.2022
CZ14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
Former [2023/26]AT14.09.2022
CZ14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
Former [2023/23]AT14.09.2022
CZ14.09.2022
EE14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
PT16.01.2023
Former [2023/22]AT14.09.2022
CZ14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
PT16.01.2023
Former [2023/20]FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
RS14.09.2022
SE14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
Former [2023/10]FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
RS14.09.2022
SE14.09.2022
NO14.12.2022
GR15.12.2022
Former [2023/09]FI14.09.2022
LT14.09.2022
LV14.09.2022
RS14.09.2022
SE14.09.2022
NO14.12.2022
Former [2023/08]FI14.09.2022
LT14.09.2022
RS14.09.2022
SE14.09.2022
NO14.12.2022
Cited inInternational search[IY]WO2006044732  (AVENTIS PHARMA INC [US], et al) [I] 1-9,12-19 * claims 1, 40 * * page 158 *[Y] 1,18;
 [Y]WO2008152093  (BAYER SCHERING PHARMA AG [DE], et al) [Y] 1,18 * claims 1, 8, 16 * * page 30, lines 11-24 *
by applicantWO2006044732
 WO2006128129
 WO2008006583
 WO2008008059
 WO2008039882
 WO2008152093
 WO2009105220
 WO2011022348
 WO2011144742
 WO2012127032
 WO2013020945
 WO2013090552
 WO2013163190
 WO2015033299
 WO2015034820
 WO2015044900
 WO2015058067
 WO2015058031
    - WANG R et al., Curr Pharm Des., (20130000), vol. 19, no. 1, pages 115 - 25
    - GARCIA RODRIGUEZ LA et al., Recent Results Cancer Res, (20130000), vol. 191, pages 67 - 93
    - SAHIN IH et al., Cancer Lett., (20140410), vol. 345, no. 2, pages 249 - 57
    - DREW DA et al., Nat Rev Cancer, (20160000), vol. 16, page 173
    - BROTONS C et al., Am J Cardiovasc Drugs., (20150400), vol. 15, no. 2, page 113
    - KUO KT et al., Ann Surg One, (20090000), vol. 16, no. 2, pages 352 - 60
    - ALAA M et al., Int J Oncol, (20090000), vol. 34, no. 3, pages 805 - 12
    - MIYATA Y et al., Urology, (20130000), vol. 81, no. 1, pages 136 - 42
    - BADAWI AF; BADR MZ, Int J Cancer., (20030000), vol. 103, no. 1, pages 84 - 90
    - GALLO 0 et al., Hum Pathol., (20020000), vol. 33, no. 7, pages 708 - 14
    - NAKANISHI M.; ROSENBERG D.W., Seminars in Immunopathology, (20130000), vol. 35, pages 123 - 137
    - FISCHER SM et al., Cancer Prev Res (Phila, (20111100), vol. 4, no. 11, pages 1728 - 35
    - FULTON AM et al., Cancer Res, (20060000), vol. 66, no. 20, pages 9794 - 97
    - YANG L et al., Cancer Res, (20060000), vol. 66, no. 19, pages 9665 - 9672
    - POZZI A. et al., JBC, vol. 279, no. 28, pages 29797 - 29804
    - SHARMA S et al., Cancer Res, (20050000), vol. 65, no. 12, pages 5211 - 5220
    - OSHIMA H et al., Gastroenterology, (20110000), vol. 140, no. 2, pages 596 - 607
    - FU SL et al., J Gastroenterol, (20040000), vol. 10, no. 13, pages 1971 - 1974
    - KUNDU N et al., Breast Cancer Res Treat, (20090000), vol. 117, pages 235 - 242
    - XIN X et al., Lab Investigation, (20120000), pages 1 - 14
    - MARKOSYAN N et al., Breast Cancer Res, (20130000), vol. 15, page R75
    - TERADA et al., Cancer Res, (20100000), vol. 70, no. 4, pages 1606 - 1615
    - AI-WADEI HA et al., PLOS One, (20120000), vol. 7, no. 8, page e43376
    - FUNAHASHI H et al., Cancer Res, (20070000), vol. 67, no. 15, pages 7068 - 71
    - NAKANISHI Y et al., Carcinogenesis, (20110000), vol. 32, pages 1333 - 39
    - SHARMA S et al., Cancer Res, (20050000), vol. 5, no. 12, pages 5211 - 20
    - SINHA P et al., Cancer Res, (20070000), vol. 67, no. 9, pages 4507 - 4513
    - OBERMAJER N et al., Blood, (20110000), vol. 118, no. 20, pages 5498 - 5505
    - BAO YS et al., Int Immunopharmacol., (20110000), vol. 11, no. 10, pages 1599 - 605
    - KIM JG; HAHN YS, Immunol Invest., (20000000), vol. 29, no. 3, pages 257 - 69
    - DEMEUERE CE et al., Eur J Immunol., (19970000), vol. 27, no. 12, pages 3526 - 31
    - MITSUHASHI M et al., J Leukoc Biol., (20040000), vol. 76, no. 2, pages 322 - 32
    - POCKAJ BA, Ann Surg Oncol., (20040000), vol. 11, no. 3, pages 328 - 39
    - SPECHT C et al., Int J Cancer, vol. 200191, pages 705 - 712
    - AHMADI M et al., Cancer Res, (20080000), vol. 68, no. 18, pages 7250 - 9
    - STOLINA M et al., J Immunol, (20000000), vol. 164, pages 361 - 70
    - ZHANG Y; DAAKA Y, Blood, (20110000), vol. 118, no. 19, pages 5355 - 64
    - JAIN S et al., Cancer Res., (20080000), vol. 68, no. 19, pages 7750 - 9
    - WANG; KLEIN, Molecular Carcinogenesis, (20070000), vol. 46, pages 912 - 923
    - KALINSKI P, J Immunol, (20120000), vol. 188, no. 1, pages 21 - 28
    - OBERMAJER N et al., Oncoimmunology, vol. 1, no. 5, pages 762 - 4
    - GREENHOUGH A, carcinogenesis, (20090000), vol. 30, no. 3, pages 377 - 86
    - WANG D; DUBOIS RN, Gut, (20060000), vol. 55, pages 115 - 122
    - HARRIS SG, Trends Immunol, (20020000), vol. 22, pages 144 - 150
    - GHOSH N et al., Pharmacol Rep., vol. 62, no. 2, pages 233 - 44
    - DAVIS TW et al., Am J Clin Oncol., (20030000), vol. 26, no. 4, pages 58 - 61
    - HIGGINS JP et al., Cancer Biol Ther, (20090000), vol. 8, pages 1440 - 49
    - ZHANG X et al., Clin Cancer Res., (20050000), vol. 11, no. 17, pages 6261 - 9
    - YAMAGUCHI NH et al., J Gastrointest Oncol., (20140000), vol. 5, no. 1, pages 57 - 66
    - GENERALI D et al., Br J Cancer., (20140000), vol. 111, no. 1, pages 46 - 54
    - LUSTBERG MB, Clin Breast Cancer., (20110800), vol. 11, no. 4, pages 221 - 7
    - FALANDRY C et al., Breast Cancer Res Treat., (20090800), vol. 116, no. 3, pages 501 - 8
    - CHOW LW et al., J Steroid Biochem Mol Biol., (20080000), vol. 111, no. 1-2, pages 13 - 7
    - MOTZ GT et al., Nat Med, (20140000), vol. 20, no. 6, page 607
    - ZHANG H et al., Oncol Res., (20130000), vol. 20, no. 10, pages 447 - 55
    - VELTMAN JD et al., BMC Cancer., (20100000), vol. 10, page 464
    - TOOMEY D, Vaccine, (20080625), vol. 26, no. 27-28, pages 3540 - 9
    - EBERSTAL S et al., Int J Cancer., (20140601), vol. 134, no. 11, pages 2748 - 53
    - EBERSTAL S et al., Cancer Immunol Immunother., (20120000), vol. 61, no. 8, pages 1191 - 9
    - HAHN T et al., Int J Cancer., (20060000), vol. 118, no. 9, pages 2220 - 31
    - DELONG P et al., Cancer Res., (20031115), vol. 63, no. 22, pages 7845 - 52
    - YONGKUI LI et al., Oncoimmunology, (20160000), vol. 5, no. 2, page e1074374
    - ZELENAY S et al., Cell, (20150000), vol. 162, pages 1 - 14
    - MANDAPATHIL M et al., J Biol Chem., (20100000), vol. 285, no. 10, pages 7176 - 86
    - HOSKIN DW et al., Int J Oncol, (20080000), vol. 32, pages 527 - 535
    - MANDAPATHIL M et al., J Biol Chem., (20100000), vol. 285, no. 36, pages 27571 - 80
    - CAIAZZO E et al., Biochem Pharmacol., (20160000), vol. 112, pages 72 - 81
    - BOYD MJ et al., bioorganic and medicinal chemistry letters, (20110000), vol. 21, page 484
    - REINOLD H et al., J Clin Invest, (20050000), vol. 115, no. 3, pages 673 - 9
    - NAKAO K et al., J Pharmacol Exp Ther., (20070800), vol. 322, no. 2, pages 686 - 94
    - HONDA T et al., J Exp Med, (20060000), vol. 203, no. 2, pages 325 - 35
    - MATSUMOTO et al., Biology of reproduction, (20010000), vol. 64, pages 1557 - 65
    - HITZAKI et al., PNAS, (19990000), vol. 96, no. 18, pages 10501 - 10506
    - TILLEY SL, J Clin Inves, (19990000), vol. 103, no. 11, pages 1539 - 45
    - KENNEDY CR et al., Nat Med, (19990000), vol. 5, no. 2, pages 217 - 20
    - SANTULLI P et al., J Clin Endocrinol Metab, (20140000), vol. 99, no. 3, pages 881 - 90
    - LEE J et al., Biol Reprod, (20130000), vol. 88, no. 3, page 77
    - LEE J et al., Fertil Steril, vol. 93, no. 8, pages 2498 - 506
    - CHUANG PC et al., Am J Pathol, (20100000), vol. 176, no. 2, pages 850 - 60
    - BANU SK et al., MOI endocrinol, (20090000), vol. 23, no. 8, pages 1291 - 305
    - ESAKI Y et al., PNAS, (20100000), vol. 107, no. 27, pages 12233 - 8
    - SCHIFFMANN S et al., Biochem Pharmacol., (20140000), vol. 87, no. 4, pages 625 - 35
    - KOFLER DM et al., J Clin Invest, (20140000), vol. 124, no. 6, pages 2513 - 22
    - KOJIMA F et al., Prostaglandins Other Lipid Mediat, (20090000), vol. 89, pages 26 - 33
    - ATTUR M et al., J Immunol., (20080000), vol. 181, no. 7, pages 5082 - 8
    - CIPOLLONE F et al., Artherioscler Thromb Vase Biol, (20050000), vol. 25, no. 9, pages 1925 - 31
    - BABAEV VR et al., Cell Metab., (20081200), vol. 8, no. 6, pages 492 - 501
    - MEDEIROS AL et al., J Exp Med, (20090000), vol. 206, no. 1, pages 61 - 8
    - CIMINO PJ et al., Curr Med Chem., (20080000), vol. 15, no. 19, pages 1863 - 9
    - LIANG X et al., Ann Neurol, (20080000), vol. 64, no. 3, pages 304 - 14
    - LIANG X et al., J Mol Neurosci, (20070000), vol. 33, no. 1, pages 94 - 9
    - JIN J et al., J Neuroinflammation, (20070000), vol. 4, page 2
    - TAKADERA T et al., Life Sci, (20060000), vol. 78, no. 16, pages 1878 - 83
    - LIANG X et al., J Neurosci, (20050000), vol. 25, no. 44, pages 10180 - 7
    - KEENE CD et al., Am J Pathol., (20100000), vol. 177, no. 1, pages 346 - 54
    - SHIE FS et al., Glia, (20050000), vol. 52, no. 1, pages 70 - 7
    - POOLER AM et al., Neurosci. Lett., (20040000), vol. 362, no. 2, pages 127 - 30
    - MONTINE TJ et al., J Neurochem, (20020000), vol. 83, no. 2, pages 463 - 70
    - HOSHINO T et al., J Neurochem, (20120000), vol. 120, no. 5, pages 795 - 805
    - ELBERG G et al., Am J Physiol Renal Physiol, (20070000), vol. 293, no. 5, pages F1622 - 32
    - SUZAWA T, Endocrinology, (20000400), vol. 141, no. 4, pages 1554 - 9
    - MIYAURA C et al., J Biol Chem, (20000000), vol. 275, no. 26, pages 19819 - 23
    - TOMITA M et al., Bone, (20020100), vol. 30, no. 1, pages 159 - 63
    - CHEMICAL ABSTRACTS, Database accession no. 1001913-77-4
    - Bioorg. Med. Chem, (20110000), vol. 21, no. 13, pages 4108 - 4114
    - Bioorg. Med. Chem, (20110000), vol. 21, no. 1, pages 66 - 75
    - Bioorg. Med. Chem, (20130000), vol. 21, no. 2, pages 540 - 546
    - Prodrugs and Targeted Delivery: Towards Better ADME Properties, Wiley, (20100000), vol. 47
    - ZELENAY et al., Cell, (20150000), vol. 162, pages 1 - 14
    - VOLENCE FJ et al., J Surg Oncol., (19800000), vol. 13, no. 1, pages 39 - 44
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.